<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tron Group Inc — News on 6ix</title>
<link>https://6ix.com/company/tron-group-inc</link>
<description>Latest news and press releases for Tron Group Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 03 Dec 2025 21:23:11 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tron-group-inc" rel="self" type="application/rss+xml" />
<item>
<title>Alchem Announces Poster Presentation on its AD=229 Program at Society for Neuroscience 2025 Conference</title>
<link>https://6ix.com/company/tron-group-inc/news/alchem-announces-poster-presentation-on-its-ad229-program-at-society-for-neuroscience-2025-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/alchem-announces-poster-presentation-on-its-ad229-program-at-society-for-neuroscience-2025-conference</guid>
<pubDate>Wed, 03 Dec 2025 21:23:11 GMT</pubDate>
<description>Alchem Announces Poster Presentation on its AD=229 Program at Society for Neuroscience 2025 Conference.</description>
</item>
<item>
<title>Dr. Aman Chauhan Presents Phase 1 Study on Neuroendocrine Tumors at ESMO 2025</title>
<link>https://6ix.com/company/tron-group-inc/news/dr-aman-chauhan-presents-phase-1-study-on-neuroendocrine-tumors-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/dr-aman-chauhan-presents-phase-1-study-on-neuroendocrine-tumors-at-esmo-2025</guid>
<pubDate>Mon, 20 Oct 2025 13:38:18 GMT</pubDate>
<description>Dr. Aman Chauhan Presents Phase 1 Study on Neuroendocrine Tumors at ESMO 2025.</description>
</item>
<item>
<title>ESMO Abstract “1709MO - Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)”</title>
<link>https://6ix.com/company/tron-group-inc/news/esmo-abstract-1709mo-multi-center-nci-sponsored-phase-i-study-of-triapine-in-combination-with-177lu-dotatate-in-patients-with-well-differentiated-gastroenteropancreatic-neuroendocrine-tumours-gep-nets</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/esmo-abstract-1709mo-multi-center-nci-sponsored-phase-i-study-of-triapine-in-combination-with-177lu-dotatate-in-patients-with-well-differentiated-gastroenteropancreatic-neuroendocrine-tumours-gep-nets</guid>
<pubDate>Mon, 13 Oct 2025 09:04:52 GMT</pubDate>
<description>ESMO Abstract “1709MO - Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)”.</description>
</item>
<item>
<title>Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025</title>
<link>https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-announces-presentation-of-national-cancer-institute-sponsored-phase-i-study-with-triapine-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-announces-presentation-of-national-cancer-institute-sponsored-phase-i-study-with-triapine-at-esmo-2025</guid>
<pubDate>Wed, 10 Sep 2025 17:11:41 GMT</pubDate>
<description>Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025.</description>
</item>
<item>
<title>Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors</title>
<link>https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-announces-end-of-patient-recruitment-for-nci-phase-ii-study-with-triapine-for-neuroendocrine-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-announces-end-of-patient-recruitment-for-nci-phase-ii-study-with-triapine-for-neuroendocrine-tumors</guid>
<pubDate>Fri, 18 Jul 2025 20:18:29 GMT</pubDate>
<description>Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors.</description>
</item>
<item>
<title>Nanopharmaceutics Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma</title>
<link>https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-inc-announces-initiation-of-clinical-study-of-triapine-radiation-for-glioblastoma-or-astrocytoma</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-inc-announces-initiation-of-clinical-study-of-triapine-radiation-for-glioblastoma-or-astrocytoma</guid>
<pubDate>Tue, 01 Apr 2025 18:30:39 GMT</pubDate>
<description>Nanopharmaceutics Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma.</description>
</item>
<item>
<title>TRON Group Inc. Announces Results of 2025 Annual Meeting of Shareholders</title>
<link>https://6ix.com/company/tron-group-inc/news/tron-group-inc-announces-results-of-2025-annual-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/tron-group-inc-announces-results-of-2025-annual-meeting-of-shareholders</guid>
<pubDate>Tue, 01 Apr 2025 13:21:15 GMT</pubDate>
<description>TRON Group Inc. Announces Results of 2025 Annual Meeting of Shareholders.</description>
</item>
<item>
<title>PRX-3140, a 5-HT4 Agonist and Sigma-1 Agonist/Antag., Modulates Glucocorticoid Insulin Suppression and Cortisol Levels</title>
<link>https://6ix.com/company/tron-group-inc/news/prx-3140-a-5-ht4-agonist-and-sigma-1-agonistantag-modulates-glucocorticoid-insulin-suppression-and-cortisol-levels</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/prx-3140-a-5-ht4-agonist-and-sigma-1-agonistantag-modulates-glucocorticoid-insulin-suppression-and-cortisol-levels</guid>
<pubDate>Thu, 12 Dec 2024 19:01:44 GMT</pubDate>
<description>PRX-3140, a 5-HT4 Agonist and Sigma-1 Agonist/Antag., Modulates Glucocorticoid Insulin Suppression and Cortisol Levels.</description>
</item>
<item>
<title>Nanopharmaceutics Announces Initiation of Clinical Study of Oral Tetrathiomolybdate Capsules in Breast Cancer Patients</title>
<link>https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-announces-initiation-of-clinical-study-of-oral-tetrathiomolybdate-capsules-in-breast-cancer-patients</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-announces-initiation-of-clinical-study-of-oral-tetrathiomolybdate-capsules-in-breast-cancer-patients</guid>
<pubDate>Fri, 11 Oct 2024 12:25:47 GMT</pubDate>
<description>Nanopharmaceutics Announces Initiation of Clinical Study of Oral Tetrathiomolybdate Capsules in Breast Cancer Patients.</description>
</item>
<item>
<title>Nanopharmaceutics, Inc. (TGRP) Changes Corporate Name back to TRON Group, Inc. and forms wholly-owned Nanopharmaceutics Subsidiary</title>
<link>https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-inc-tgrp-changes-corporate-name-back-to-tron-group-inc-and-forms-wholly-owned-nanopharmaceutics-subsidiary</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-inc-tgrp-changes-corporate-name-back-to-tron-group-inc-and-forms-wholly-owned-nanopharmaceutics-subsidiary</guid>
<pubDate>Thu, 06 Jun 2024 12:52:07 GMT</pubDate>
<description>Nanopharmaceutics, Inc. (TGRP) Changes Corporate Name back to TRON Group, Inc. and forms wholly-owned Nanopharmaceutics Subsidiary.</description>
</item>
<item>
<title>Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa</title>
<link>https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-and-northwestern-university-announce-initiation-of-phase-i-adaptive-dose-escalation-clinical-study-with-dose-expansion-of-oral-triapiner-in-combination-with-temozolomide-tmz-for-pa</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-and-northwestern-university-announce-initiation-of-phase-i-adaptive-dose-escalation-clinical-study-with-dose-expansion-of-oral-triapiner-in-combination-with-temozolomide-tmz-for-pa</guid>
<pubDate>Tue, 14 May 2024 20:53:17 GMT</pubDate>
<description>Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa.</description>
</item>
<item>
<title>PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics</title>
<link>https://6ix.com/company/tron-group-inc/news/precisionlife-announces-strategic-cns-drug-development-collaboration-with-nanopharmaceutics</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/precisionlife-announces-strategic-cns-drug-development-collaboration-with-nanopharmaceutics</guid>
<pubDate>Thu, 15 Jun 2023 14:45:57 GMT</pubDate>
<description>PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics.</description>
</item>
<item>
<title>Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Triapine</title>
<link>https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-inc-announces-the-end-of-patient-recruitment-for-the-national-cancer-institute-nci-sponsored-phase-3-clinical-study-in-advanced-stage-cervical-and-vaginal-cancers-with-triapine</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/nanopharmaceutics-inc-announces-the-end-of-patient-recruitment-for-the-national-cancer-institute-nci-sponsored-phase-3-clinical-study-in-advanced-stage-cervical-and-vaginal-cancers-with-triapine</guid>
<pubDate>Wed, 02 Nov 2022 14:11:47 GMT</pubDate>
<description>Nanopharmaceutics, Inc. Announces the End of Patient Recruitment for the National Cancer Institute (NCI) Sponsored Phase 3 Clinical Study in Advanced-Stage Cervical and Vaginal Cancers with Triapine.</description>
</item>
<item>
<title>TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement</title>
<link>https://6ix.com/company/tron-group-inc/news/tron-group-inc-and-nanopharmaceutics-inc-announce-definitive-merger-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/tron-group-inc-and-nanopharmaceutics-inc-announce-definitive-merger-agreement</guid>
<pubDate>Thu, 11 Aug 2022 19:04:42 GMT</pubDate>
<description>TRON Group, Inc. and Nanopharmaceutics, Inc. Announce Definitive Merger Agreement.</description>
</item>
<item>
<title>TRON Group Announces Entertainment Rights Acquisition</title>
<link>https://6ix.com/company/tron-group-inc/news/tron-group-announces-entertainment-rights-acquisition</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/tron-group-announces-entertainment-rights-acquisition</guid>
<pubDate>Mon, 23 Aug 2021 13:01:15 GMT</pubDate>
<description>TRON Group Announces Entertainment Rights Acquisition.</description>
</item>
<item>
<title>TRON Group Announces Partnership with Legend 3D for Visual Effects Services and Education</title>
<link>https://6ix.com/company/tron-group-inc/news/tron-group-announces-partnership-with-legend-3d-for-visual-effects-services-and-education</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/tron-group-announces-partnership-with-legend-3d-for-visual-effects-services-and-education</guid>
<pubDate>Tue, 17 Aug 2021 13:03:21 GMT</pubDate>
<description>TRON Group Announces Partnership with Legend 3D for Visual Effects Services and Education.</description>
</item>
<item>
<title>TRON Group Inc. Acquires Digital Engineering Corporation ("DEC") to be Cornerstone of R&D Division and to Manage Technology Portfolio</title>
<link>https://6ix.com/company/tron-group-inc/news/tron-group-inc-acquires-digital-engineering-corporation-dec-to-be-cornerstone-of-randd-division-and-to-manage-technology-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/tron-group-inc-acquires-digital-engineering-corporation-dec-to-be-cornerstone-of-randd-division-and-to-manage-technology-portfolio</guid>
<pubDate>Thu, 08 Jul 2021 13:01:52 GMT</pubDate>
<description>TRON Group Inc. Acquires Digital Engineering Corporation ("DEC") to be Cornerstone of R&D Division and to Manage Technology Portfolio.</description>
</item>
<item>
<title>TRON Group Inc. Acquires American Crypto Systems, Inc in Expansion into U.S. Crypto Markets</title>
<link>https://6ix.com/company/tron-group-inc/news/tron-group-inc-acquires-american-crypto-systems-inc-in-expansion-into-us-crypto-markets</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/tron-group-inc-acquires-american-crypto-systems-inc-in-expansion-into-us-crypto-markets</guid>
<pubDate>Tue, 06 Jul 2021 13:31:22 GMT</pubDate>
<description>TRON Group Inc. Acquires American Crypto Systems, Inc in Expansion into U.S. Crypto Markets.</description>
</item>
<item>
<title>OTC Markets Group Welcomes Newly Verified OTCQB Companies – July 19</title>
<link>https://6ix.com/company/tron-group-inc/news/otc-markets-group-welcomes-newly-verified-otcqb-companies-july-19</link>
<guid isPermaLink="true">https://6ix.com/company/tron-group-inc/news/otc-markets-group-welcomes-newly-verified-otcqb-companies-july-19</guid>
<pubDate>Tue, 19 Jul 2016 11:00:00 GMT</pubDate>
<description>OTC Markets Group Welcomes Newly Verified OTCQB Companies – July 19.</description>
</item>
</channel>
</rss>